Summary.

Vaccines capable of controlling neoplastic and infectious diseases which depend on the cellular immune response for their resolution, have proven difficult to develop. We, and others, have previously demonstrated that the potent immunogenicity of hepatitis B surface antigen (HBsAg), the already-licensed human vaccine for hepatitis B infection, may be exploited to deliver foreign antigens for cytotoxic T-lymphocyte (CTL) induction. In this study we demonstrate that recombinant (r) HBsAg DNA delivering a CTL polyepitope appended at the C' terminus elicits concomitant responses to multiple epitopes restricted through a diversity of MHC class I haplotypes, which are relevant in a number of human diseases. We show that the rHBsAg DNA vaccine elicits concomitant protection against neoplastic and infectious disease. These studies vindicate the use of HBsAg as a powerful vector to deliver
Introduction
Vaccine strategies other than attenuated or killed whole organism vaccines, capable of safely and effectively inducing cellular and humoral responses in humans have not proven easy to develop 1 .
The small envelope protein of hepatitis B surface antigen (HBsAg-S) self-assembles into highly organised virus-like particles (VLPs) in yeast, insect cells and mammalian cells 2 . HBsAg VLPs are exploited as the current globally licensed vaccine for Hepatitis B virus infection in humans (including children). The vaccine has a long history in millions of recipients, inviting the usage of HBsAg as a vector for delivery of immunogens from other infectious diseases and tumors.
Regulatory issues surrounding HBsAg vaccines containing foreign disease-associated immunogens may be less stringent than for other approaches.
The HBsAg VLP vaccine generates strong B cell immunity, comparing favourably with traditional strong immune response inducers 3 . The ability of this vaccine to also induce cellular responses may be linked to CTL epitope density that occurs in VLPs and/or the ability of VLPs to be easily endocytosed 4 . HBsAg may also be delivered as a DNA vaccine 5, 6 . Using DNA as immunogen, CTL induction by intracellular translated HBsAg protein occurs through the 'classical' endogenous pathway and may occur through the 'alternative' exogenous pathway via secreted HBsAg particles or protein 7, 8 . However powerful immune responses to HBsAg DNA vaccine are obtained even in the absence of VLP formation. Whether the HBsAg protein has a specific characteristic that complements the way that DNA vaccines are presented to the immune system, whether it is from some intrinsic adjuvant-like characteristic or provision of T-'help', remains unclear.
DNA-based vaccines hold particular promise as an option to prevent and treat infections and some tumors 9 . While clinical trials have hitherto shown that the magnitude of immune responses primed by standard DNA vaccines is generally weaker in humans than in small mammals, a number of strategies (eg. targeting antigen to the endoplasmic reticulum or dendritic cells, using adjuvants, prime-boost regimens and/or use of cytokines) have been explored to overcome this. One approach which particularly shows promise for HBsAg is electoporation or ballistic delivery of DNA directly into the skin 10 . A number of these 'new generation' approaches to DNA vaccination in humans is now underway 11 , and the immunological results of trials appear similar to the results we and others have obtained in mice 12 .
We have previously reported a novel strategy for generating cellular immunity using
HBsAg vector by deleting HBsAg-specific CTL epitopes and replacing them with foreign CTL epitopes of similar physical properties (ie. size and hydrophobicity) 13, 14 . In addition, other groups have extended the C' and/or N' termini of HBsAg with whole antigens and shown that such vaccines can induce protective immunity [15] [16] [17] [18] . While we have previously highlighted the enormous potential of HBsAg as a potential generic vaccine framework for inducing potent protective immunity 19 , it is clear that this potential is only just being realised .
The demonstration that multiple CTL epitopes may by linked linearly to form a polyepitope vaccine 20 suggests the possibility of simultaneous protection against multiple diseases, by encoding epitopes from a number of different pathogens. In the present study we explored HBsAg DNA as a vector to deliver DNA encoding a polyepitope comprising eight murine and human disease-protective CTL epitopes. We demonstrate that immunization of mice induced CTL responses to all eight foreign epitopes. We also demonstrate that CTL responses were associated with protection against neoplastic and infectious diseases.
These data underscore the efficacy of HBsAg DNA as a powerful vector to elicit CTL responses to multiple foreign epitopes encoded within a DNA polyepitope. They also demonstrate the capacity of rHBsAg DNA to deliver simultaneous protective immunity against multiple diseases.
Results
pHBsAg-Polyepitope#3
The essential features of the HBsAg-polyepitope construct (pHBsAg-Polyepitope#3) are depicted in Fig 1. Mammalian codon optimisation of HBsAg and the CTL polyepitope C'terminal extension was used to predispose to enhanced polyprotein production. To minimise internal initiation of truncated proteins, we preferentially selected epitopes without methionine residues, and those two epitopes ( LLM and YLL) which did contain a methionine residue were included at the extreme N' terminus. The epitopes included in the polyepitope were previously described to elicit disease-protective CTL responses in murine models of human disease (Table   1) . Individual epitopes were separated by hydrophilic 'spacer' sequences to reduce the overall hydrophobicity of the polyepitope. Additionally, an arginine residue was included at the C' terminus of each epitope, in order to maximise antigen processing and immunogenicity 21 .
Immunization with pHBsAg-Polyepitope#3 DNA elicits CTL responses to each encoded foreign epitope. Fig. 3B ).
Restimulated splenocytes from pHBsAg W/T-immunized mice did not secrete levels of IFN-γ above background , or kill peptide pulsed target cells (data not shown).
We were concerned that although the above immunization regimen elicited responses to seven of the eight foreign epitopes encoded by pHBsAg-Polyepitope#3, no response was elicited to epitope LLM. To address this we adopted a prime-boost approach. Immunization with pHBsAg-Polyepitope#3 confers protection against pulmonary hRSV infection.
We asked whether immunization of groups of mice with pHBsAg-Polyepitope#3 (which expresses a hRSV CTL epitope; ESY, Table 1 Immunization with pHBsAg-Multiepitope#2, encoding foreign CTL epitopes inserted into the HBsAg backbone, elicits multiple CTL responses.
We have previously shown that rHBsAg DNA vaccines in which sequences encoding endogenous HBsAg CTL epitopes are deleted from the HBsAg backbone and replaced with DNA encoding a foreign epitope, elicit CTL responses to the inserted foreign epitope 22 . We wished to examine whether a rHBsAg vaccine encoding multiple epitopes inserted into the HBsAg backbone might also be effective in eliciting CTL responses relevant to multiple diseases. We constructed, using this epitope replacement strategy , a rHBsAg DNA vaccine (pHBsAg-Multiepitope#2) containing six of the eight CTL epitopes listed in Table 1 , inserted into the HBsAg backbone (   Fig 7) . We examined the efficacy of induction of CTL responses, capable of killing target cells displaying the encoded foreign epitopes. Splenocytes from mice immunized with HBsAgMultiepitope#2 or pHBsAg W/T were restimulated for 6 days in vitro with each of the six encoded foreign epitopes, and reacted in ELISPOT assay. A higher number of splenocytes from mice immunized with pHBsAg-Multiepitope#3 secreted IFN-γ when cultured in vitro with peptides GIL, ESY, RAH, and KLI, (but not but not VGA or LLM (not shown)), than without peptide (Fig. 8A ).In addition, restimulated splenocytes specifically killed cognate epitope-pulsed , but not unpulsed, target cells (Fig 8B ) . Restimulated splenocytes from pHBsAg W/T immunized mice did not secrete levels of IFN-γ above background , or kill peptide pulsed target cells (not shown).
These data indicate that CTL responses to foreign epitopes may be elicited by a rHBsAg DNA vaccine encoding multiple disease-relevant foreign CTL epitopes inserted into the HBsAg backbone.
Discussion
In this study we have constructed a human codon optimised recombinant HBsAg DNA vaccine The observation that CTL-mediated disease resolution is usually focussed on one or a few epitopes 23 and that a majority of human MHC class I polymorphism is contained with relatively few epitope cross-presenting class I 'supertypes' 24 , suggests that wide population coverage against a substantial number of diseases may be feasible with C'terminal polyepitope extensions containing relatively few CTL epitopes.
In this study, we also extend our previous observations 25 . This pathway has likely evolved to deal with nascent proteins from the ribosome machinery, and it has been demonstrated that particle formation within the APC is not required for endogenous processing of the HBsAg polyprotein. 34 . Whether secretion of HBsAg polyprotein and/or particles, eg. from DNA transfected muscle cells, provides a second mechanism for HBsAg CTL generation via the exogenous pathway 35 is controversial 36, 37 . Data generated from a matched series of plasma DNA vectors expressing wild-type or several mutant forms of HBsAg that were secretion-defective, or severely truncated, indicated that neither VLP formation nor it's secretion or liberation plays a significant part in the development of the CTL response 38 .
In summary, DNA-based HBsAg immunization is extremely potent, and may be explained by prolonged or higher expression, high epitope density, superior antigen processing, the presence of multiple T-helper epitopes 39, 40 , biasing the response via cytokines to a Th1profile 41 and, possibly in some circumstances, secretion for uptake of polyprotein/particle by This measure predisposes the polyepitope to an external (to the particle) location. We also elected to exclude epitopes containing cysteine residues, thereby minimising perturbation in secondary structure due to disulphide bonding. The lack of VLP formation is in contrast to rHBsAg C'-terminally extended with a HIV polyepitope where some VLP production was recorded. 46 . It underscores findings of our laboratory and others 47, 48 on the relative lack of predictability of VLP-forming propensity by HBsAg engineered to contain foreign sequences. In this study we demonstrate that recombinant HBsAg delivering a CTL polyepitope appended at the C' terminus elicits concomitant responses to multiple epitopes restricted through a diversity of MHC class I haplotypes, which are relevant in a number of human diseases. We
show that the rHBsAg vaccine elicits concomitant protection against neoplastic and infectious disease. These studies vindicate the use of HBsAg as a powerful vector to deliver CTL responses to foreign antigens. They also have have implications for a multi-disease vaccine applicable to the HLA-polymorphic human population.
Materials and Methods
pHBsAg-Polyepitope#3
The hepatitis B surface antigen codon sequence of Valenzuela et.al. 49 was used as a basis for the codon optimization of the gene using codons described by Cid-Arregui et al 50 . The sequence data has been submitted to the Genbank database under accession number xxx.
Essentially, oligonucleotides were synthesized as 80mers (Geneworks, Australia) which covered the full length sequence of the HBsAg in the 5' to 3' direction. A series of CTL epitopes were interspersed with spacer regions comprising the sequences HWSISKPQ, RAKT, RADT, RDTA or RTKA. (Fig. 1) . Spacer sequence HWSISKPQ is mimotope of a hRSV Fprotein B-cell epitope 51 . Other spacer sequences are as described 52 . A set of complementary oligonucleotides were also synthesized which overlapped the termini of the forward oligonucleotides by 40 bases. Each oligonucleotide was then added to a PCR reaction at a concentration of 5ng/ul in the presence of PrimeSTAR HS DNA polymerase (Takara Bio Inc, Shiga, Japan). PCR reaction conditions were as described by the manufacturer. The PCR product was purified from a 1% agarose gel after electrophoresis using UltraClean GelSpin cartridges (Mo Bio Labs Inc, CA) according to the manufacturer's instructions and then incubated in the presence of dNTPs (10mM) and Taq DNA polymerase (Promega, USA) for the addition of 3'-teminal adenosine residues. The DNA was ligated into pGEM-T easy vector (Promega, USA) using T4DNA ligase (Promega, USA) according to the manufacturer's instructions. The DNA insert into the pGEM-T easy plasmid was sequenced in both directions and any errors in the sequence corrected using the QuickChange II site-directed mutagenesis kit (Stratagene TX, USA).
pHBsAg-Multiepitope#2.
pHBsAg-Multiepitope #2 was derived essentially as described 53 . In summary, the plasmid pcD3-HBsAgS (ayw subtype) 54 was engineered to delete the HBsAg-specific CTL epitopes ( 
Immunization and restimulation of splenocytes
Mice were immunized intradermally (id.) in the ear as with 100 ug of purified plasmid DNA prepared by EndoFree Plasmid Giga Kit (Qiagen, Australia). Two weeks after immunization, spleens were removed and splenocytes were restimulated in vitro for 6 days as described 57 with 1ug/ml cognate peptide. For peptide immunizations, mice were immunized subcutaneously (sc.)
at the tail base with 50ug peptide + 0.25ug tetanus toxoid (TT) as a source of T-helper epitopes + 10ug Quil A adjuvant 58 . Ten days later spleens were harvested and splenocytes were restimulated as above.
Cells.
EL4.A2 cells 59 are susceptible to specific CTL lysis through both H-2 b and HLA A*0201 restriction pathways. P815 is susceptible to specific CTL lysis through the H-2 d restriction pathway. Cells were maintained as described 60 .
Murine IFN-γ ELISPOT assay.
Epitope-specific gamma interferon (IFN-γ) secreting spleen cells were enumerated ex vivo by an enzyme-linked immunospot (ELISPOT) assay with minimal CD8 + T-cell epitope peptides, essentially as described 61 . IFN-γ spots were counted using an AID ELISPOT reader system.
Results were calculated as IFN-γ positive cells/10 6 spleen cells. 51 Cr-release CTL assay.
CTL assays were conducted as previously described 62 . In summary, target cells ( Tumor protection assays. Data are also presented as Kaplan Meier tumor incidence curves of % tumor free mice at given time points after tumor injection.
Propagation of RSV and evaluation of pulmonary viral infection.
hRSV A2 (VR-1302) strain (American Type Culture Collection , Rockville, MD, USA) was propagated in HEp-2 cells essentially as described 65 and recovered from the supernatant following freeze/thawing of monolayers displaying a cytopathic effect.
hRSV was quantified by immunofocus assay, using goat anti-hRSV primary antibody (Chemicon, Australia), anti-goat Ig horse-radish peroxidase conjugated second antibody, and tetraaminobiphenyl hydrochloride substrate (Sigma, Australia), according to manufacturer's instructions. Lungs were collected 4 days after mice were inoculated intranasally (in.) with 8x10 5 plaque forming units (pfu) and RSV quantified in lung homogenates by immunofocus assay as described 66 .
Statistics.
Experimental values were compared for significant difference using Student's t-test. Kaplan
Meier tumor incidence curves were compared using the Log Rank statistic. or not pulsed (triangle symbols) with LLM peptide in a 51 Chromium cytotoxicity assay. Data points represent means of three replicates +/-standard deviations (standard deviations were <5%). 
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